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a b s t r a c t
Discontinuation of ﬁngolimod in patients with multiple sclerosis (MS) can lead to disease
reactivation. In this review, we describe cases of severe exacerbations in patients with MS
following discontinuation of ﬁngolimod, including three cases from our center. We consider
potential mechanisms of disease reactivation after cessation of ﬁngolimod, and the evi-
dence supporting this rebound effect. We conclude that discontinuation of ﬁngolimod
results in the return of disease activity, which then leads to severe exacerbations (i.e.,
rebounds) in a clinically signiﬁcant proportion of patients. Lastly, we consider disease-
modifying treatment options for patients who discontinue ﬁngolimod.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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The availability of highly effective disease-modifying treat-
ments (DMTs) has profoundly improved the management of
patients with relapsing-remitting multiple sclerosis (RRMS).
For instance, ﬁngolimod nearly halves the frequency of
relapses, and natalizumab reduces the relapse rate by
approximately 70% [1]. However, the beneﬁts of these
therapies can be accompanied by serious complications,
which were not observed with ﬁrst-line DMTs (i.e., interferon
beta, glatiramer acetate). On one hand, modern DMTs have
increased the risk of opportunistic infections, including the
potentially life-threatening viral disease, progressive multifo-
cal leukoencephalopathy (PML) [2]. On the other hand,
discontinuation of DMTs can cause severe disease reactiva-
tion, which can result in debilitating, and often irreversible,* Corresponding author at: Second Department of Neurology, Institut
Poland. Tel.: +48 22 45 82 537; fax: +48 22 84 24 023.
E-mail address: czlonkow@ipin.edu.pl (A. Członkowska).
http://dx.doi.org/10.1016/j.pjnns.2017.01.006
0028-3843/© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Ndisease progression. These factors cause dilemmas in clinical
decision making, when treatment discontinuation is consid-
ered.
In this review, we describe cases of severe disease
reactivation in patients with MS, following ﬁngolimod discon-
tinuation, including cases from our center. Moreover, we
consider possible mechanisms of disease reactivation after
ﬁngolimod cessation and the evidence supporting the rebound
effect. Lastly, we consider DMT options for patients who
discontinue ﬁngolimod treatment.
2. Cases of severe disease reactivation after
ﬁngolimod discontinuation
Since 2012, over twenty cases of severe disease reactivation
following ﬁngolimod discontinuation have been describede of Psychiatry and Neurology, ul. Sobieskiego 9, 02-957 Warsaw,
eurological Society.
Table 1 – Multiple sclerosis patients with disease reactivation following fingolimod withdrawal.
Gender Age
(years)
Reason for
discontinuation
Time
to ﬁrst
relapse
(months)
Lymphocyte
recovery
Multiple
new lesions
(>10)
Treatment
during relapse
DMT after
relapse
References
F 47 SPMS 5 N/S Yes MP None [3]
F 30 Genital herpes 3 N/S Yes MP Natalizumab [3]
M 53 Completion of RCT 3 N/S No MP None (PPMS) [4]
M 60 Completion of RCT 4 N/S No MP plus oral taper None (PPMS) [4]
F 35 Breast cancer 1.5 Yes Yes MP, rituximab Rituximab [14]
F 30 Planned pregnancy 1.5 Yes No (9) MP Fingolimod [14]
F 28 Planned pregnancy 1 Yes Yes MP plus oral taper Rituximab [14]
F 45 Adverse effects 1.5 Yes Yes MP and
dexamethasone,
rituximab
Dimethyl fumarate [14]
F 35 Patient decision 1.5 No Yes MP Fingolimod [14]
F 20 Lymphopenia 3 No Yes MP plus oral taper Dimethyl fumarate [20]
F 41 SAH 3 No Yes MP, PE Fingolimod [20]
F 30 Increased
transaminases
3 No Yes MP, PE Dimethyl fumarate [20]
M 53 Melanoma 3 Yes Yes MP Natalizumab [8]
F 31 Planned pregnancy 2 N/S N/S MP N/S [9]
F 44 Lymphopenia 3 Yes No MP, intrathecal
triamcinolone
Dimethyl fumarate [30]
F 36 Angina pectoris 2 Yes No MP Dimethyl fumarate [30]
F 29 Viral neuritis 4 No Yes MP plus oral taper Interferon-beta [33]
F 36 Lymphopenia 2 Yes Yes MP Glatiramer acetate [34]
F 19 Lack of efﬁcacy 2 Yes Yes MP, PE Cyclophosphamide [34]
F 33 Patient decision 3 Yes Yes MP Cyclophosphamide [36]
F 31 Planned pregnancy 3 N/S Yes MP None, relapse
during pregnancy
[37]
F 36 Lymphopenia 2 Yes Yes MP plus oral taper N/S [38]
F 32 Lymphopenia 1 Yes Yes MP, immune adsorption Natalizumab [39]
Age, at ﬁngolimod discontinuation; DMT, disease modifying therapy; F, female; M, male, MP, intravenous methylprednisolone; N/S, not
speciﬁed; PE, plasma exchange; SAH, subarachnoid hemorrhage; SPMS, secondary progressive multiple sclerosis; UTI, urinary tract infection.
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profound worsening of the neurological state, typically accom-
panied by the appearance of numerous gadolinium-enhancing
(Gd+) lesions on brain magnetic resonance images (MRIs; Fig. 1).
Although these exacerbations were nearly exclusively observed
in patients with RRMS, one case of severe disease reactivation
occurred in a patient that had discontinued ﬁngolimod due to
entrance into the secondary progressive phase of MS (SPMS) [3].
Moreover, in a recent report, Davion et al. [4] described two
patients with primary progressive MS who experienced
signiﬁcant exacerbations after discontinuing ﬁngolimod, upon
completion of the INFORMS study. Those two patients
exhibited single Gd+ lesions in strategic locations: the
brainstem and the spinal cord.
In our center, we observed three patients with MS who
experienced signiﬁcant disease reactivation following ﬁngo-
limod cessation (Table 2). We present these case studies below.
2.1. Patient 1
After starting ﬁngolimod therapy at the age of 34 years, this
female patient experienced complete clinical remission over a
3-year period (EDSS = 5.0). However, the treatment was
discontinued, due to lymphopenia complicated by several
urinary tract infections. Two months later, the patient
relapsed with right hemiparesis and ataxia (EDSS = 6.5).Treatment with intravenous methylprednisolone (MP) could
not provide functional improvement. Within the next 2 weeks,
she developed tetraparesis, bulbar syndrome, dysarthria, and
respiratory insufﬁciency, which required transient mechani-
cal ventilation (EDSS = 9.5). On the MRI, numerous Gd+ lesions
were detected in the brain and cervical spinal cord (Fig. 1A–C).
After ruling out neuroinfection (including a negative ﬁnding in
a cerebrospinal ﬂuid DNA study for the JC virus), we
administered intravenous MP again, and a plasma exchange.
This treatment resulted in an improvement (EDSS = 7.5), but
despite subsequent treatment with cyclophosphamide, we
observed further debilitating deterioration (EDSS = 9.0). A long-
term follow-up examination showed that her functional state
had not improved.
2.2. Patient 2
After 3 years of treatment with no change in the disability
score (EDSS = 4.5), this 25-year-old woman decided to discon-
tinue ﬁngolimod due to several upper respiratory tract and
urinary tract infections. Two months after withdrawal, she
was admitted due to a signiﬁcant exacerbation, with lower
limb paresis and ataxia (EDSS = 6.0). A brain MRI showed
multiple Gd+ lesions. She received intravenous MP and
improved after physical therapy (EDSS = 3.0). She refused to
receive any alternative DMTs.
Fig. 1 – T1-weighted magnetic resonance images after gadolinium (Gd) administration in patients with severe exacerbations
after discontinuation of fingolimod. (A–C) (patient 1) – Gd+ lesions are located in both brain hemispheres and in the cervical
spinal cord; (D–F) (patient 3) – multiple Gd+ lesions are located in both brain hemispheres, including a large cluster of lesions
in the right frontal lobe.
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After more than 10 years of ﬁngolimod treatment, this 53-year-
old man discontinued treatment due to an episode of atrial
ﬁbrillation (EDSS = 1.5 at treatment initiation; after several
relapses, he entered SPMS with EDSS = 6.0; Table 2). Atrial
ﬁbrillation occurred during treatment with MP for a minor
deterioration, with no change in the functional state (left lower
limb weakness, EDSS = 6.0). Two months later, he was re-
admitted due to left upper limb weakness (EDSS = 6.0). A brain
MRI showed multiple Gd+ lesions in both hemispheres,
including a large cluster of lesions in the right frontal lobe
(Fig. 1D–F). After ruling out neuroinfection (including a
negative ﬁnding in a cerebrospinal ﬂuid DNA study for the
JC virus), the patient was given intravenous MP with an oral
taper, which resulted in an improvement (EDSS = 5.5).
3. Rebound effect
It is understandable that withdrawing immunosuppressive
agents in patients with immune-mediated diseases can lead to
disease recurrence. For instance, this has been observed in
myasthenia gravis [5] and psoriasis [6], and it is one of the
reasons for transplant rejection. In some patients, the level of
reactivation can surpass pretreatment activity levels; thus, it is
often referred to as a 'rebound' effect. This effect has also been
discussed in the context of severe disease reactivationfollowing discontinuation of both natalizumab and ﬁngolimod
[7–9]. According to our understanding, we might expect that
rebound reactivation would increase disease activity indices,
like annualized relapse rates (ARRs) and the number of Gd+
lesions, to levels above those observed before a given
treatment. However, a precise, widely accepted deﬁnition of
rebound has not been established for patients with RRMS;
thus, it is difﬁcult to conduct further investigations of this
issue. The most useful deﬁnition would encompass both
clinical and neuroimaging measures. In addition, it would
preferably include some laboratory parameters, like restora-
tion of lymphocyte counts or speciﬁc lymphocyte subpopula-
tions, at speciﬁed time windows after treatment cessation.
Based on studies performed to date, it can be concluded
that discontinuation of both ﬁngolimod and natalizumab can
lead to reactivation of disease, but the indices of disease
activity did not surpass those of the pretreatment period.
Although O'Connor et al. [10] noted a return of disease activity
after withdrawal of natalizumab, they did not observe a
rebound in terms of the clinical relapse activity (n = 1886) or in
the number of Gd+ lesions (n = 341), compared to placebo
treatment. Similar results were reported by Sorensen et al. [11],
despite the fact that, in that study, over 20% of patients who
discontinued natalizumab fulﬁlled the clinical criteria of a
rebound (ARRs higher than pretreatment rates). Likewise,
among 421 patients who discontinued ﬁngolimod, after a
mean follow-up of 153 days, the mean ARR and the number of
Gd+ lesions were comparable to baseline values [12]. On the
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discontinued ﬁngolimod reported rebound disease activity
after ﬁngolimod cessation in 7.7% (2/26) and 10.9% (5/46) of
patients [13,14]. In the study by Gunduz et al. [13], the criteria
for a rebound were not put forward clearly, and the post-
discontinuation disease activity in two patients was described
as severe relapses, ‘‘suggesting a rebound effect’’. In the study
by Hatcher et al. [14], rebound was deﬁned as new, severe
neurological symptoms accompanied by multiple new or Gd+
lesions that exceeded baseline activity.
One might consider whether the reported disease reactiva-
tion following discontinuation of highly-effective treatments,
used predominantly in patients with more aggressive disease
course, is the result of a clear-cut contrast between disease
activity during the treatment and post-treatment periods.
Interestingly, one study reported that, among patients with a
high pretreatment disease activity that showed a good
response to interferon-beta, 65% experienced at least one
severe relapse after treatment discontinuation [15].
In patients who discontinued natalizumab, those of
younger ages that showed high pretreatment disease activity
were at a greater risk of signiﬁcant exacerbations after
discontinuation than the other patients [7]. However, no
factors are known to predict the response to ﬁngolimod
discontinuation.
In conclusion, discontinuations of ﬁngolimod and natali-
zumab result in the return of disease activity. Moreover, in a
clinically signiﬁcant proportion of patients, discontinuation
leads to severe exacerbations that could be described as
rebounds.
4. Potential mechanisms of disease
reactivation following ﬁngolimod discontinuation
in MS
It is thought that ﬁngolimod acts in MS by interfering with
lymphocyte egress from secondary lymphoid tissues by
binding to and downregulating the expression of lymphocytic
sphingosine-1-phosphate receptors 1 (S1P1). Fingolimod selec-
tively retains T cells that express the CCR7 receptor, including
central memory cells and CCR7-positive naïve T cells [16]. This
retention is reﬂected by a decrease in peripheral blood
lymphocyte count (lymphopenia). Discontinuation of ﬁngoli-
mod is followed by a reconstitution of lymphocyte counts
within 4–8 weeks, although in some patients with MS,
lymphopenia can be detected for over 2 years after discontin-
uation [17].
Stopping ﬁngolimod treatment in a relapsing-remitting
model of experimental autoimmune encephalomyelitis (EAE)
resulted in severe disease recurrence [18]. Recurrence was
preceded by an overexpression of S1P1 in lymph node-residing
lymphocytes, which prompted their egress. In another EAE
study, a similar exacerbating effect was observed on disease
severity when ﬁngolimod treatment was stopped [19]. In that
study, animals that received both ﬁngolimod and cyclosporine
displayed signiﬁcant exacerbations after only ﬁngolimod was
discontinued; in contrast, animals treated with cyclosporine
alone throughout the experiment displayed a stable disease
course.
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of the immune system might lead to a return of inﬂammatory
activity within the central nervous system, similar to
observations in animal models. This hypothesis was sup-
ported by the fact that the majority of patients with severe
disease reactivation following ﬁngolimod discontinuation
experienced initial symptoms within approximately 3 months
of ﬁngolimod cessation, upon the recovery of lymphocyte
counts (Table 1). However, we and other authors have
observed disease reactivation after ﬁngolimod withdrawal in
patients who had remained lymphopenic [14,20]. This ﬁnding
might be explained by the fact that reactivation of neuroin-
ﬂammatory activity depends on speciﬁc lymphocyte popula-
tions, regardless of the general lymphocyte count. For
instance, patients with MS that relapsed during ﬁngolimod
treatment exhibited signiﬁcantly higher proportions of central
memory T-cells in peripheral blood than patients who
remained relapse-free, despite the fact that these groups
had comparable lymphocyte counts [21].
The state of clinical disease reactivation following ﬁngo-
limod cessation, accompanied by immune system reconstitu-
tion, has been compared to the immune reconstitution
inﬂammatory syndrome (IRIS) [8,20]. Initially, IRIS was
described in patients with HIV-infections. Upon initiation of
the highly-active antiretroviral therapy (HAART), the restora-
tion of immune system function led to an exceedingly potent
reaction to previously acquired opportunistic infections. For
instance, an initially subclinical viral infection, like tuberculo-
sis or cryptococcosis, might present with neurological man-
ifestations upon HAART initiation [22]. Notably, this response
was also observed in patients who discontinued natalizumab
due to PML; exacerbations were observed for days to weeks
after a plasma exchange had been instituted to expedite
natalizumab clearance [23]. However, a broader deﬁnition of
IRIS can include autoimmune reactions, such as the reactiva-
tion of MS following cessation of ﬁngolimod, with no evidence
of prior infection [24]. Because IRIS is associated with a rapid
restoration of immune function, one might suspect that a
tapered discontinuation of ﬁngolimod would lead to a less
potent response. This strategy was shown to be beneﬁcial for
patients who discontinued natalizumab [25]. The use of
reduced doses of ﬁngolimod has been reported in 8 patients
with MS, but evaluating the beneﬁt of this strategy requires a
larger trial, which is currently under way [26].
It has been shown that patients with HIV who had a history
of IRIS displayed increased serum IL-6 levels [27]. Similarly, in
an animal model of stromal keratitis, an increased IL-6
concentration was observed after discontinuing ﬁngolimod,
and this increase was associated with recurrence of inﬂamma-
tory lesions [28]. Moreover, neutralization of this cytokine with
a monoclonal antibody resulted in diminished lesion forma-
tion. Those ﬁndings suggested a potential rescue treatment
with IL-6 receptor inhibitors; e.g., tocilizumab has shown
promising results in patients with neuromyelitis optica [29].
5. Treatment of rebound syndromes
Despite the fact that patients with rebound syndrome often
present with severe clinical manifestations, the only availabletreatment options are those used for all relapses. The typical
treatment is a high dose of intravenous corticosteroids, with or
without an oral taper. Moreover, one patient treated with
intrathecal triamcinolone showed improvement [30]. In
patients resistant to glucocorticosteroids, some improvement
was observed with antibody-depleting strategies, such as
plasma exchange and immune adsorption.
6. DMTs after ﬁngolimod
With the growing number of available DMTs, it has become
increasingly complex to transition between different agents.
To date, there is no evidence in favor of any particular DMT
after ﬁngolimod cessation. Thus, different agents have been
administered in different centers to patients who experienced
severe exacerbation after ﬁngolimod cessation (Table 1).
Because ﬁngolimod has been shown to reduce disease
reactivation following natalizumab cessation [31], a reverse
approach might be effective. Because both drugs interfere with
immune cell trafﬁcking, it seems plausible that natalizumab
could act on immune cells that are redistributed from the
lymph nodes by restraining them from entering the central
nervous system.
Dimethyl fumarate (DMF) is an alternative for patients who
agree to receive exclusively oral therapy. However, three cases
of severe disease exacerbation have been described in patients
who had transitioned from ﬁngolimod to DMF [14,30]. Because
teriﬂunomide is less efﬁcacious, it is not expected to be a good
alternative to ﬁngolimod. The same would apply to other ﬁrst-
line agents, namely, interferon beta and glatiramer acetate.
Another alternative, rituximab was previously tested in two
patients with rebound syndromes after ﬁngolimod cessation
[14]. However, one of the patients experienced an exacerba-
tion, despite having received the ﬁrst infusion before symptom
onset. Moreover, that patient continued to develop new
lesions, despite receiving subsequent doses.
Another group of DMTs that could offer an alternative
approach to patients who discontinue ﬁngolimod are induc-
tion agents, such as alemtuzumab or mitoxantrone [32]. These
DMTs would be particularly suitable for women planning
pregnancy (a frequent reason for discontinuation), because
currently, no DMTs are safe for maintained treatment in
pregnant women. However, this approach would signiﬁcantly
postpone the time for a safe conception. For instance, the two
courses of alemtuzumab are administered 1 year apart, and
pregnancy must be delayed for 4 months after the last
infusion.
7. Conclusions
Discontinuation of ﬁngolimod can lead to a return of disease
activity. In a clinically signiﬁcant proportion of patients,
ﬁngolimod discontinuation will result in severe exacerbations
that could be described as rebounds. With the growing use of
ﬁngolimod, this issue will become relevant in clinical practice.
To address this issue, we need to establish multi-center
registries of patients who discontinue ﬁngolimod. That data
would facilitate investigations of potential risk factors for
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compare the effectiveness of particular treatment regimens
given after ﬁngolimod discontinuation. However, prior to that
endeavor, an explicit deﬁnition of rebound should be
established.
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